Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 164Breast Neoplasms 111Colorectal Neoplasms 77Neoplasms 65Lung Neoplasms 61Pancreatic Neoplasms 56Stomach Neoplasms 52Neoplasm Metastasis 51Ovarian Neoplasms 45Rectal Neoplasms 43Esophageal Squamous Cell Carcinoma 38Esophageal Neoplasms 38Head and Neck Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Leukemia, Myeloid, Acute 32Recurrence 26Triple Negative Breast Neoplasms 25Small Cell Lung Carcinoma 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Glioblastoma 23Colonic Neoplasms 23Uterine Cervical Neoplasms 22Nasopharyngeal Carcinoma 22Lymphoma 21Lymphoma, Non-Hodgkin 20Fallopian Tube Neoplasms 20Prostatic Neoplasms 17Melanoma 17Sarcoma 16Leukemia 16

Interventions

trastuzumab biosimilar HLX02 2ribociclib 2pertuzumab 2durvalumab 2Trastuzumab 2Taxes 2Specimen Handling 2Paclitaxel 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Drug Therapy 2Docetaxel 2Disulfides 22C4 antibody 2tucatinib 1tremelimumab 1exemestane 1bintrafusp alfa protein, human 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1High-Energy Shock Waves 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anatomic Stage II Breast Cancer AJCC v8 × Drug Therapy × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT05710328 2026-05-05

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
235 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡